- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01817699
Correcting Anemia and Native Vitamin D Supplementation in Kidney Transplant Recipients (CANDLE-KIT)
A Factorial Randomized Controlled Trial of Correcting Anemia and Native Vitamin D Supplementation in Kidney Transplant Recipients
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
Sample size estimation:
The previous trial (the CAPRIT study) showed that 2.0 g/dL increase of hemoglobin (Hb) reduced 69% of 2-year decline in estimated glomerular filtration rate (eGFR) (Choukroun G, et al. J Am Soc Nephrol, 2012). Given that the annual eGFR decline in our patients with Hb level <10.5 g/dL was 1.66 (SD, 2.47) mL/min per 1.73 m2, the investigators hypothesized that the 2-year eGFR decline in the conservative anemia management group and the aggressive anemia correction group should be 3.32 (SD, 4.94) and 1.03 (SD, 4.94) mL/min per 1.73 m2, respectively. In order to compare the actual efficacy of the intervention with the assumptions above and to evaluate the need for an early termination of the trial, the investigators will perform one interim analysis using a Pocock type α-spending function when a total of 50-60% of the target sample size completed this study or dropped out. Assuming 20% of dropout or lost-to-follow, the planned sample size of 272 patients would yield a power of 90% for group comparison by using t-test with a type I error of 5%.
Regarding cholecalciferol supplementation, 1,000 IU/day would increase serum 25-hydroxyvitamin D level by 11.8 ng/mL in patients with BMI <30, as suggested by the previous trial (Gallagher JC, et al. Ann Intern Med, 2012). The investigators found in our prospective cohort study that the 98.2% of Japanese kidney transplant recipients had BMI <30, and that 10 ng/mL increase in 25-hydroxyvitamin D level was significantly associated with 0.75 mL/min/1.73 m2 less decrease in annual eGFR change independent of potential confounders (in submission). As with the anemia intervention arms above, the investigators will perform one interim analysis using a Pocock type α-spending function when a total of 50-60% of the target sample size completed this study or dropped out in order to compare the actual efficacy of the intervention with the assumptions above and to evaluate the need for an early termination of the trial. Therefore, the investigators expect 1.77 mL/min per 1.73 m2 in eGFR would be preserved by 1,000 IU/day of cholecalciferol supplementation for 2 years. Based on this assumption, this study size will provide a power of 70%.
Estimating kidney function:
In primary analyses, eGFR will be calculated by using the Japanese equation as in sample size calculation (Matsuo S, et al. Am J Kidney Dis, 2009). However, this formula has not yet been validated in kidney transplant recipients. Therefore, the investigators will use the creatinine-based CKD-EPI equation with Japanese coefficient (Stevens LA, et al. Nephrol Dial Transplant, 2010. Horio M, et al. Am J Kidney Dis, 2010) and an available formula if validated in Japanese kidney transplant recipients at the time of analysis.
Statistical analyses:
For group comparison in a primary analysis, the investigators will use t-test or Wilcoxon rank sum test according to the distribution of eGFR change. In the further analyses, to analyze the time course of eGFR with respect to treatment assignment, changes in eGFR over time will be analyzed with a linear mixed model for repeated measures with both fixed and random intercept and slope. The multivariate model will contain time-varying eGFR as dependent variable and treatment group as well as the number of measurements (time) as independent variables. The study hypothesis will be tested by adding appropriate interaction terms between the exposures and time. For secondary endpoints, the investigators will use t-test, Wilcoxon rank sum test, or log-rank test for group comparison, and generalized linear models or Cox proportional hazards models to estimate each effect of the interventions, appropriately. The investigators will also adjust for baseline levels or past history of each outcome. Other potential confounders, such as age, sex, time since transplantation, blood pressure, urinary protein level, and diabetes, will be adjusted in sensitivity analyses.
The interaction will be checked between anemia management and cholecalciferol supplementation as well as between each intervention and baseline levels of urinary protein, eGFR, Hb, 25-hydroxyvitamin D, the use of active vitamin D compounds, and the length of time since transplantation. Additionally, stratified analyses will be conducted according to 0.2 g/g・creatinine of urinary protein and the date of transplantation (November 1999, the release date of mycophenolate mofetil in Japan). However, the study size is not large enough to statistically evaluate these interactions. The results from these analyses should be interpreted with caution and regarded as exploratory and hypothesis generating.
Missing values:
Missing values will not be imputed in primary analyses. In sensitivity analyses, the investigators will use multiple imputation method and last-observation-carried-forward method.
Note:
The interim analysis plan was added to the protocol with an increase in the sample size from 246 to 272, which has been approved by the local ethics committee on August 27, 2018.
Studietype
Registrering (Faktiske)
Fase
- Fase 4
Kontakter og plasseringer
Studiesteder
-
-
Osaka
-
Suita, Osaka, Japan, 565-0871
- CANDLE Trial Study Group
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- ≥15 and <60 ml/min per 1.73 m2 of estimated glomerular filtration rate
- Transplanted allograft kidney at least 1 year before
- <10.5 g/dL of Hb without iron deficiency (serum ferritin level ≥50 ng/ml) or on erythropoiesis stimulating agents treatment regardless of iron status
- With written informed consent
Exclusion Criteria:
- On anticancer treatment
- History of ischemic stroke or transient ischemic attack
- Corrected serum calcium ≥10.5 mg/dL
- HIV virus infection
- Anticipated refractory hypertension by using epoetin beta pegol
- In pregnancy and lactation
- Current use of native vitamin D supplement
- Patients ineligible according to the investigator's judgement
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Faktoriell oppgave
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Ingen inngripen: Low Hb target without cholecalciferol
Target Hemoglobin level: ≥9.5 and <10.5 g/dL
|
|
Aktiv komparator: Low Hb target with cholecalciferol
Target Hemoglobin level: ≥9.5 and <10.5 g/dL Cholecalciferol: 1,000 IU/day
|
1,000 IU (1 tablet)/day, orally.
Tablets are repacked into blister package.
Andre navn:
|
Aktiv komparator: High Hb target without cholecalciferol
Target Hemoglobin level: ≥12.5 and <13.5 g/dL
|
25 to 250 μg of methoxy polyethylene glycol epoetin beta (Mircera®, Chugai pharmaceutical Co. Ltd.) will be administered subcutaneously at 2- to 6-week interval. Dose and interval will be adjusted according to hemoglobin level and its target. |
Eksperimentell: High Hb target with cholecalciferol
Target Hemoglobin level: ≥12.5 and <13.5 g/dL Cholecalciferol: 1,000 IU/day
|
1,000 IU (1 tablet)/day, orally.
Tablets are repacked into blister package.
Andre navn:
25 to 250 μg of methoxy polyethylene glycol epoetin beta (Mircera®, Chugai pharmaceutical Co. Ltd.) will be administered subcutaneously at 2- to 6-week interval. Dose and interval will be adjusted according to hemoglobin level and its target. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Change in allograft kidney function
Tidsramme: 2 years
|
As allograft kidney function, GFR is estimated by the modified MDRD equation for Japanese patients with chronic kidney disease.
|
2 years
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Blodtrykk
Tidsramme: 2 år
|
2 år
|
|
Urine markers of kidney injury
Tidsramme: 6 months
|
|
6 months
|
The dose of methoxy polyethylene glycol epoetin beta required to maintain the target hemoglobin level
Tidsramme: 1 year
|
For vitamin D supplementation study only.
|
1 year
|
Cardiac biomarkers
Tidsramme: 2 years
|
|
2 years
|
Left ventricular mass index
Tidsramme: 2 years
|
2 years
|
|
Biopsy-proven acute cellular rejection
Tidsramme: 2 years
|
2 years
|
|
Bone-turnover markers
Tidsramme: 6 months
|
For vitamin D supplementation study only. |
6 months
|
Bone mineral density of lumber spine and femoral neck.
Tidsramme: 2 years
|
For vitamin D supplementation study only.
|
2 years
|
Hypercalcemia
Tidsramme: 2 years
|
Corrected calcium ≥11 mg/dL For vitamin D supplementation study only. |
2 years
|
Time to the renal composite endpoint
Tidsramme: 2 years
|
renal composite endpoint consists of 50% increase in serum creatinine, subsequent transplantation, and reinitiation of dialysis.
|
2 years
|
Time to admission-required cardiovascular events
Tidsramme: 2 years
|
Cardiovascular events includes myocardial infarction, angina, congestive heart failure, stroke, and peripheral artery disease.
|
2 years
|
Time to all-cause death
Tidsramme: 2 years
|
2 years
|
|
Time to Cancer development or recurrence
Tidsramme: 2 years
|
2 years
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
C-reactive protein
Tidsramme: 1 year
|
For vitamin D supplementation study only.
|
1 year
|
Time to the adverse composite endpoint
Tidsramme: 2 years
|
The adverse composite endpoint consists of death, admission-required cardiovascular diseases, and the renal composite endpoint.
|
2 years
|
Time to hospitalization for opportunistic infections
Tidsramme: 2 years
|
Opportunistic infections includes polyomavirus-associated nephropathy, tuberculosis, Pneumocystis carinii pneumonia, cytomegalovirus infection, herpes zoster, bacterial pneumonia. For vitamin D supplementation study only. |
2 years
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Studieleder: Takayuki Hamano, MD, PhD, Department of Inter-Organ Communication Research in Kidney Disease, Osaka University Graduate School of Medicine
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A; Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009 Jun;53(6):982-92. doi: 10.1053/j.ajkd.2008.12.034. Epub 2009 Apr 1.
- Gallagher JC, Sai A, Templin T 2nd, Smith L. Dose response to vitamin D supplementation in postmenopausal women: a randomized trial. Ann Intern Med. 2012 Mar 20;156(6):425-37. doi: 10.7326/0003-4819-156-6-201203200-00005. Erratum In: Ann Intern Med. 2012 May 1;156(9):672.
- Choukroun G, Kamar N, Dussol B, Etienne I, Cassuto-Viguier E, Toupance O, Glowacki F, Moulin B, Lebranchu Y, Touchard G, Jaureguy M, Pallet N, Le Meur Y, Rostaing L, Martinez F; CAPRIT study Investigators. Correction of postkidney transplant anemia reduces progression of allograft nephropathy. J Am Soc Nephrol. 2012 Feb;23(2):360-8. doi: 10.1681/ASN.2011060546. Epub 2011 Dec 22.
- Stevens LA, Schmid CH, Zhang YL, Coresh J, Manzi J, Landis R, Bakoush O, Contreras G, Genuth S, Klintmalm GB, Poggio E, Rossing P, Rule AD, Weir MR, Kusek J, Greene T, Levey AS. Development and validation of GFR-estimating equations using diabetes, transplant and weight. Nephrol Dial Transplant. 2010 Feb;25(2):449-57. doi: 10.1093/ndt/gfp510. Epub 2009 Sep 30.
- Horio M, Imai E, Yasuda Y, Watanabe T, Matsuo S. Modification of the CKD epidemiology collaboration (CKD-EPI) equation for Japanese: accuracy and use for population estimates. Am J Kidney Dis. 2010 Jul;56(1):32-8. doi: 10.1053/j.ajkd.2010.02.344. Epub 2010 Apr 22.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Nyresykdommer
- Urologiske sykdommer
- Hematologiske sykdommer
- Ernæringsforstyrrelser
- Avitaminose
- Mangelsykdommer
- Underernæring
- Nyresvikt, kronisk
- Vitamin D-mangel
- Nyreinsuffisiens
- Anemi
- Fysiologiske effekter av legemidler
- Mikronæringsstoffer
- Vitaminer
- Bone Density Conservation Agents
- Kalsiumregulerende hormoner og midler
- Vitamin d
- Kolekalsiferol
Andre studie-ID-numre
- CKDR-001
- UMIN000009970 (Registeridentifikator: UMIN Clinical Trials Registry)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Nyresvikt, kronisk
-
Clínica de Oftalmología de Cali S.AFullførtMeibomian kjerteldysfunksjon | Eyes Dry ChronicColombia
-
Universitaire Ziekenhuizen KU LeuvenFullførtForekomst av utvidet renal clearance | Risikofaktorer for økt renal clearanceBelgia
-
Alcon ResearchFullført
-
Andrew B AdamsBristol-Myers SquibbFullført
-
University Health Network, TorontoFullførtGlomerulær filtreringshastighet | Renal blodstrømCanada
-
Jules Bordet InstituteMacopharma; Belgian Hematological SocietyRekrutteringRefractory Chronic Graft Versus Host Disease (cGVHD)Belgia
-
Oregon Health and Science UniversityFullført
-
Erling Bjerregaard PedersenUniversity of AarhusUkjentRenal rørtransportDanmark
-
Amai Charitable TrustUkjent
-
The Methodist Hospital Research InstituteUkjentAkutt (cellulær) renal allograft avvisningForente stater
Kliniske studier på cholecalciferol
-
King Faisal Specialist Hospital & Research CenterFullført
-
Saiful Anwar HospitalFullført
-
University Hospital, Clermont-FerrandCRINEX Laboratory; BP 337 - 3 rue de Gentilly; 92541 MONTROUGE Cedex FRANCEUkjentLeddgikt | Vitamin D-mangelFrankrike
-
Hospital Infantil de Mexico Federico GomezRekrutteringVitamin D-mangel | Cystisk fibrose | Cystisk fibrose Lungeforverring | Cystisk fibrose hos barn | Bentetthet, lav | Kronisk betennelseMexico
-
Bispebjerg HospitalRigshospitalet, DenmarkUkjent
-
Karaganda Medical UniversityFullførtKronisk obstruktiv lungesykdom | Kronisk obstruktiv lungesykdom Moderat | Kronisk obstruktiv lungesykdom AlvorligKasakhstan
-
Instituto Nacional de Ciencias Medicas y Nutricion...UkjentNyreinsuffisiens | Vitamin D-mangel | Sluttstadium nyresvikt ved dialyse | Vaskulær forkalkningMexico
-
Shanghai Jiao Tong University School of MedicineHar ikke rekruttert ennå